Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker NKTR
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Aug 18, 2026 | Jonathan Zalevsky Chief R&D Officer | NKTR Nektar Therapeutics | Sale | 186 | $71.98 | $13.4K Sale | Form 4 ↗ |
| Aug 18, 2026 | Howard W. Robin President & CEO, Director | NKTR Nektar Therapeutics | Sale | 418 | $71.98 | $30.1K Sale | Form 4 ↗ |
| Jun 30, 2026 | Jonathan Zalevsky Chief R&D Officer | NKTR Nektar Therapeutics | Sale | 5,681 | $70.00 | $397.7K Sale | Form 4 ↗ |
| Jun 17, 2026 | Howard W. Robin President & CEO, Director | NKTR Nektar Therapeutics | Sale | 4,500 | $61.65 | $277.4K Sale | Form 4 ↗ |
| Jun 17, 2026 | Howard W. Robin President & CEO, Director | NKTR Nektar Therapeutics | Sale | 5,500 | $60.81 | $334.5K Sale | Form 4 ↗ |
| Jun 16, 2026 | Howard W. Robin President & CEO, Director | NKTR Nektar Therapeutics | Sale | 4,697 | $60.71 | $285.2K Sale | Form 4 ↗ |
| Jun 16, 2026 | Howard W. Robin President & CEO, Director | NKTR Nektar Therapeutics | Sale | 5,303 | $59.97 | $318.0K Sale | Form 4 ↗ |
| Jun 15, 2026 | Jonathan Zalevsky Chief R&D Officer | NKTR Nektar Therapeutics | Sale | 5,538 | $60.71 | $336.2K Sale | Form 4 ↗ |
| May 19, 2026 | Jonathan Zalevsky Chief R&D Officer | NKTR Nektar Therapeutics | Sale | 199 | $65.51 | $13.0K Sale | Form 4 ↗ |
| May 19, 2026 | Howard W. Robin President & CEO, Director | NKTR Nektar Therapeutics | Sale | 444 | $65.51 | $29.1K Sale | Form 4 ↗ |
| Feb 18, 2026 | Jonathan Zalevsky Chief R&D Officer | NKTR Nektar Therapeutics | Sale | 180 | $73.00 | $13.1K Sale | Form 4 ↗ |
| Feb 18, 2026 | Howard W. Robin President & CEO, Director | NKTR Nektar Therapeutics | Sale | 423 | $73.00 | $30.9K Sale | Form 4 ↗ |
| Jan 20, 2026 | Jonathan Zalevsky Chief R&D Officer | NKTR Nektar Therapeutics | Sale | 3,867 | $35.67 | $137.9K Sale | Form 4 ↗ |
| Nov 25, 2025 | Jonathan Zalevsky Chief R&D Officer | NKTR Nektar Therapeutics | Sale | 1,157 | $54.28 | $62.8K Sale | Form 4 ↗ |
| Nov 25, 2025 | Mark Andrew Wilson Chief Legal Officer | NKTR Nektar Therapeutics | Sale | 630 | $54.28 | $34.2K Sale | Form 4 ↗ |
| Nov 25, 2025 | Howard W. Robin President & CEO, Director | NKTR Nektar Therapeutics | Sale | 2,207 | $54.28 | $119.8K Sale | Form 4 ↗ |
| Sep 9, 2025 | Howard W. Robin President & CEO, Director | NKTR Nektar Therapeutics | Sale | 1,210 | $48.18 | $58.3K Sale | Form 4 ↗ |
| Sep 9, 2025 | Howard W. Robin President & CEO, Director | NKTR Nektar Therapeutics | Sale | 2,156 | $47.49 | $102.4K Sale | Form 4 ↗ |
| Sep 9, 2025 | Howard W. Robin President & CEO, Director | NKTR Nektar Therapeutics | Sale | 1,200 | $46.41 | $55.7K Sale | Form 4 ↗ |
| Sep 9, 2025 | Howard W. Robin President & CEO, Director | NKTR Nektar Therapeutics | Sale | 2,100 | $45.16 | $94.8K Sale | Form 4 ↗ |
| Sep 5, 2025 | Howard W. Robin President & CEO, Director | NKTR Nektar Therapeutics | Sale | 1,136 | $39.89 | $45.3K Sale | Form 4 ↗ |
| Sep 5, 2025 | Howard W. Robin President & CEO, Director | NKTR Nektar Therapeutics | Sale | 2,226 | $38.82 | $86.4K Sale | Form 4 ↗ |
| Sep 5, 2025 | Howard W. Robin President & CEO, Director | NKTR Nektar Therapeutics | Sale | 3,304 | $37.87 | $125.1K Sale | Form 4 ↗ |
| Sep 4, 2025 | Jonathan Zalevsky Chief R&D Officer | NKTR Nektar Therapeutics | Sale | 307 | $35.69 | $11.0K Sale | Form 4 ↗ |
| Sep 4, 2025 | Jonathan Zalevsky Chief R&D Officer | NKTR Nektar Therapeutics | Sale | 189 | $34.41 | $6,503 Sale | Form 4 ↗ |
| Sep 4, 2025 | Jonathan Zalevsky Chief R&D Officer | NKTR Nektar Therapeutics | Sale | 432 | $33.60 | $14.5K Sale | Form 4 ↗ |
| Sep 4, 2025 | Jonathan Zalevsky Chief R&D Officer | NKTR Nektar Therapeutics | Sale | 793 | $32.43 | $25.7K Sale | Form 4 ↗ |
| Sep 4, 2025 | Howard W. Robin President & CEO, Director | NKTR Nektar Therapeutics | Sale | 1,134 | $35.80 | $40.6K Sale | Form 4 ↗ |
| Sep 4, 2025 | Howard W. Robin President & CEO, Director | NKTR Nektar Therapeutics | Sale | 613 | $34.40 | $21.1K Sale | Form 4 ↗ |
| Sep 4, 2025 | Howard W. Robin President & CEO, Director | NKTR Nektar Therapeutics | Sale | 1,496 | $33.54 | $50.2K Sale | Form 4 ↗ |
| Sep 4, 2025 | Howard W. Robin President & CEO, Director | NKTR Nektar Therapeutics | Sale | 1,923 | $32.37 | $62.2K Sale | Form 4 ↗ |
| Sep 2, 2025 | Jonathan Zalevsky Chief R&D Officer | NKTR Nektar Therapeutics | Sale | 485 | $30.10 | $14.6K Sale | Form 4 ↗ |
| Sep 2, 2025 | Howard W. Robin President & CEO, Director | NKTR Nektar Therapeutics | Sale | 1,500 | $30.16 | $45.2K Sale | Form 4 ↗ |
| Aug 19, 2025 | Jonathan Zalevsky Chief R&D Officer | NKTR Nektar Therapeutics | Sale | 725 | $26.59 | $19.3K Sale | Form 4 ↗ |
| Aug 19, 2025 | Mark Andrew Wilson Chief Legal Officer | NKTR Nektar Therapeutics | Sale | 676 | $26.59 | $18.0K Sale | Form 4 ↗ |
| Aug 19, 2025 | Howard W. Robin President & CEO, Director | NKTR Nektar Therapeutics | Sale | 1,573 | $26.59 | $41.8K Sale | Form 4 ↗ |
| May 19, 2025 | Jonathan Zalevsky Chief R&D Officer | NKTR Nektar Therapeutics | Sale | 10,712 | $0.67 | $7,177 Sale | Form 4 ↗ |
| May 19, 2025 | Mark Andrew Wilson Chief Legal Officer | NKTR Nektar Therapeutics | Sale | 9,996 | $0.67 | $6,697 Sale | Form 4 ↗ |
| May 19, 2025 | Howard W. Robin President & CEO, Director | NKTR Nektar Therapeutics | Sale | 23,208 | $0.67 | $15.5K Sale | Form 4 ↗ |
| Feb 19, 2025 | Jonathan Zalevsky Chief R&D Officer | NKTR Nektar Therapeutics | Sale | 10,300 | $1.01 | $10.4K Sale | Form 4 ↗ |
| Feb 19, 2025 | Mark Andrew Wilson Chief Legal Officer | NKTR Nektar Therapeutics | Sale | 11,040 | $1.01 | $11.2K Sale | Form 4 ↗ |
| Feb 19, 2025 | Howard W. Robin President & CEO, Director | NKTR Nektar Therapeutics | Sale | 23,774 | $1.01 | $24.0K Sale | Form 4 ↗ |
| Dec 24, 2024 | Mark Andrew Wilson Chief Legal Officer | NKTR Nektar Therapeutics | Sale | 16,560 | $0.89 | $14.7K Sale | Form 4 ↗ |
| Dec 23, 2024 | Mark Andrew Wilson Chief Legal Officer | NKTR Nektar Therapeutics | Sale | 33,402 | $0.90 | $30.1K Sale | Form 4 ↗ |
| Dec 19, 2024 | Jonathan Zalevsky Chief R&D Officer | NKTR Nektar Therapeutics | Sale | 51,115 | $0.94 | $48.0K Sale | Form 4 ↗ |
| Dec 18, 2024 | Howard W. Robin President & CEO, Director | NKTR Nektar Therapeutics | Sale | 85,035 | $0.99 | $84.2K Sale | Form 4 ↗ |
| Dec 17, 2024 | Howard W. Robin President & CEO, Director | NKTR Nektar Therapeutics | Sale | 46,995 | $1.01 | $47.5K Sale | Form 4 ↗ |
| Nov 19, 2024 | Jonathan Zalevsky Chief R&D Officer | NKTR Nektar Therapeutics | Sale | 7,785 | $1.01 | $7,863 Sale | Form 4 ↗ |
| Nov 19, 2024 | Mark Andrew Wilson Chief Legal Officer | NKTR Nektar Therapeutics | Sale | 6,407 | $1.01 | $6,471 Sale | Form 4 ↗ |
| Nov 19, 2024 | Howard W. Robin President & CEO, Director | NKTR Nektar Therapeutics | Sale | 16,278 | $1.01 | $16.4K Sale | Form 4 ↗ |
50 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 5:51 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances